Shorts

0:56

The Excitement Brewing Around Plixorafenib in BRAF-Altered Cancers

a month ago

Macarena de la Fuente, MD

After the 2026 National ICE-T Conference in Charlotte, North Carolina, Barry Paul, MD, spoke with CancerNetwork® about key points of discussion in the multiple myeloma paradigm, which included the potential role of fixed-duration therapy with bispecific antibodies.

0:46

Finding a “Sweet Spot” for Fixed-Duration Multiple Myeloma Therapy

a month ago

Barry Paul, MD

Prerna Mewawalla, MD, spoke with CancerNetwork® about key takeaways from a presentation she gave at the 2026 National ICE-T Conference in Charlotte, North Carolina, which focused on the multiple myeloma therapeutic landscape.

0:33

Therapy is Only as Good as Its Access in Multiple Myeloma Care

a month ago

Prerna Mewawalla, MD

0:49

How Emotional Intelligence Can Reduce Physician Burnout

a month ago

MinhTri Nguyen, MD

Craig H. Moskowitz, MD, highlighted a trend where treatment is initiated following initial diagnosis and staging in lymphoma, which he believes may be unnecessary.

0:48

Waiting for Molecular Marker Test Results to Optimize Lymphoma Care

a month ago

Craig H. Moskowitz, MD

Following the 2026 National ICE-T Conference in Charlotte, North Carolina, CancerNetwork® spoke with conference director Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, about the key takeaways of a session that focused on the expanding roles of bispecific antibodies and T-cell engagers in multiple myeloma, lymphoma, and leukemia.

0:49

Bridging Gaps of Care Via Bispecific Antibodies in Hematologic Oncology

a month ago

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

1:02

Addressing Bottlenecks to Cancer Care in Rural Settings

a month ago

MinhTri Nguyen, MD

Using genomic profiling to identify specific fusion partners to p16 among patients with translocation renal cell carcinoma has been challenging, according to Shikha Gupta, PhD.

0:58

Larger Studies Needed to Elucidate Fusion Partner to p16 in tRRC

a month ago

Shikha Gupta, PhD

1:00

Inching Closer to Taming KRAS in Pancreatic Cancer With New Advancements

a month ago

Asfar Azmi, PhD

Isaac Allen, PhD, noted how, generally speaking, uptake levels of conservative management have increased significantly over time, foregrounded by an NCCN recommendation as the optimal choice for low-risk disease.

1:15

Who is Most Likely to Undergo Conservative Management for Prostate Cancer?

a month ago

Isaac Allen, PhD

0:50

From Chemotherapy To T-Cells: The Evolution of Cancer Treatment

a month ago

Ralph V. Boccia, MD, FACP

0:40

Why Multidisciplinary Teams Matter in Rare Cancer

a month ago

Steven Bialick, DO

In a conversation with CancerNetwork®, Lyudmila Bazhenova, MD, FASCO, detailed efficacy data from a pooled population of patients with ROS1-positive tyrosine kinase inhibitor (TKI)–naïve non–small cell lung cancer (NSCLC) who received taletrectinib (Ibtrozi) in the phase 2 TRUST-I (NCT04395677) and TRUST-II trials (NCT04919811), which she presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

0:40

Taletrectinib Produces High, Durable Responses in ROS1+ NSCLC Trials

a month ago

Lyudmila Bazhenova, MD, PhD

0:45

Are Oral SERDs Better Than Standard Therapy in Breast Cancer?

a month ago

Sara M. Tolaney, MD, MPH

Alex Herrera, MD, discussed the cumulative benefit of nivolumab plus doxorubicin, vinblastine, and dacarbazine among patients with untreated stage III or IV classical Hodgkin lymphoma based on findings from the phase 3 SWOG S1826 trial.

1:23

Nivolumab/AVD Study Represents “Unicorn Trial” in Advanced Hodgkin Lymphoma

a month ago

Alex Herrera, MD

0:40

Tebentafusp Doubles Survival Rates in Metastatic Uveal Melanoma

a month ago

Paul Nathan, MBBS, PhD, MCRP

In a conversation with CancerNetwork®, M. Umair Mushtaq, MD, highlighted the clinical utility that novel cereblon E3 ligase modulatory drugs (CELMoDs) like mezigdomide and iberdomide may play in an increasingly active multiple myeloma treatment field.

0:50

CELMoDs May Be “Uniquely Positioned” in Multiple Myeloma Treatment Paradigm

a month ago

Muhammad Umair Mushtaq, MD

Alex Herrera, MD, discussed the efficacy data from the phase 3 SWOG S1826 trial, which supported the March 2026 approval of nivolumab plus AVD among patients with untreated stage III or IV Hodgkin lymphoma.

1:13

Highlighting the Blanket Benefit of Nivo+AVD in Hodgkin Lymphoma

a month ago

Alex Herrera, MD

Diane Simeone, MD, spoke about findings with daraxonrasib in metastatic pretreated pancreatic cancer during an interview with CancerNetwork.

0:46

The Adverse Effects of Daraxonrasib in Pretreated mPDAC

a month ago

Diane Simeone, MD

Shebli Atrash, MD, spoke with CancerNetwork® about optimizing the treatment decision-making process as it relates to the use of BCMA-directed bispecific antibodies and CAR T-cell therapies among patients with multiple myeloma.

0:56

How to Sequence CAR T-Cell Therapy, Bispecifics in Multiple Myeloma

a month ago

Shebli Atrash, MD

0:29

How AI is Helping Assess Breast Cancer Risk

2 months ago

Elizabeth A. Mittendorf, MD, PhD

Heath Skinner, MD, PhD, discussed emerging technologies that help make his practice more efficient, specifically highlighting the role of AI to help optimize contouring of organs at risk vs normal tissue prior to initiating radiotherapy for patients with head and neck cancers.

0:54

AI-Based Contouring Could Optimize Treatment Planning in HNC Groups

2 months ago

Heath Skinner, MD, PhD

0:38

The KEYNOTE-B96 Regimen in PROC: What Were the Immune-Mediated AEs?

2 months ago

Bradley J. Monk, MD

Jason Starr, DO, highlighted a case report wherein a patient received EML4-ALK–targeting treatment and was taken off of hospice, experiencing more than 3 years of survival.

0:51

From Hospice to 3+ Year Survival: Extending Life in EML4-ALK Fusion NEC

2 months ago

Jason Starr, DO

1:05

AI is Changing Breast Cancer Screening

2 months ago

Cancer Network Staff

0:58

Reducing Melanoma Toxicity in Adoptive Cell Therapy

2 months ago

Jose Lutzky, MD

Wendy Stock, MD, spoke with CancerNetwork® about the safety of Orca-T during transplantation for patients with hematologic malignancies such acute lymphoblastic leukemia, acute myeloid leukemia, and myelodysplastic syndrome based on reports from the phase 3 Precision-T trial (NCT04013685).

0:47

How Safe is Orca-T During Transplantation for Hematologic Malignancies?

2 months ago

Wendy Stock, MD

In a conversation with CancerNetwork® at the 3rd Biennial Miami Precision Medicine Conference, Craig H. Moskowitz, MD, discussed the gradually diminishing role that autologous stem cell transplant (ASCT) is playing in the modern lymphoma landscape with the rise of novel treatment modalities.

0:56

Autologous Stem Cell Transplantation is Having a “Slow Death” in Lymphoma

2 months ago

Craig H. Moskowitz, MD

According to Jeff P. Sharman, despite displaying a profound impact on solid tumors, immune checkpoint inhibition has not been explored robustly in lymphomas.

0:43

Is There a Future for Immune Checkpoint Inhibition in Lymphoma?

2 months ago

Jeff P. Sharman, MD

In a discussion with CancerNetwork®, Miranda Gogishvili, MD, spoke about updated efficacy data from the phase 3 EMPOWER-Lung 1 trial (NCT03088540) that she and colleagues presented at the 2026 European Lung Cancer Congress.

Shorts

Trending on CancerNetwork

BCMA CAR T-Cell Therapy Improves OS Vs Teclistamab in Multiple Myeloma

FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer

GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence

Decoding RAMPART: Durvalumab Monotherapy Vs Combination Therapy in RCC

Ivonescimab Combo Yields Encouraging Activity in Previously Treated SCLC